(Boursier.com) — AbbVie , the American biopharmaceutical group, missed the sales consensus for the quarter, with slowdowns on flagship products such as Botox and Juvederm. The group speaks today of temporary economic headwinds, thus affecting the performance of its portfolio of cosmetic treatments. Sales of Botox for cosmetic use came in at $637 million, versus consensus of $640 million. Those of Juvederm were 352 million, against 360 million expected. The group’s total revenue rose 3.3% to $14.8 billion, versus the consensus $14.9 billion. The group’s net profit rose all the same by 24% to 3.95 billion dollars. In addition, sales of Skyrizi, a new treatment for psoriasis, exceeded expectations at $1.4 billion.